News
While net income remains relatively thin, the business is scaling efficientlyand doing so across a growing number of ...
Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.
The company reported adjusted earnings per share of $0.28 on revenue of $586 million – a significant rise compared to last ...
Hims & Hers Health, Inc.'s subscriber growth, Novo Nordisk partnership, and FDA pill approval could boost financials. Click ...
Hims & Hers Health Inc. posted better-than-expected first-quarter revenue as the company pivots away from making copycat ...
But Hims & Hers' shares fell in after-hours trading as second-quarter projections fell short of analysts' expectations. The ...
Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...
Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...
Hims & Hers Health shares are trading marginally lower Monday morning. The company earlier appointed Nader Kabbani as its new ...
24/7 Wall St. on MSN19h
Hims & Hers (HIMS) Blows Out Earnings ExpectationsHims & Hers Health (NYSE:HIMS) reported a strong financial performance for Q1 2025, with revenue reaching $586 million, ...
Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply reduced price on several telehealth ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback